None of the authors have any financial, commercial, professional or any other conflict of interest to declare, regarding this manuscript.
Molecular epidemiology of hepatitis C genotype 6a from patients with chronic hepatitis C from Hong Kong†
Article first published online: 23 FEB 2009
Copyright © 2009 Wiley-Liss, Inc.
Journal of Medical Virology
Volume 81, Issue 4, pages 628–633, April 2009
How to Cite
Li, C. S.Y., Chan, P. K.S. and Tang, J. W. (2009), Molecular epidemiology of hepatitis C genotype 6a from patients with chronic hepatitis C from Hong Kong. J. Med. Virol., 81: 628–633. doi: 10.1002/jmv.21430
- Issue published online: 23 FEB 2009
- Article first published online: 23 FEB 2009
- Manuscript Accepted: 27 NOV 2008
- Chinese University of Hong Kong made (to J.W.T.). Grant Number: 2041281
- HCV 6a;
There have been relatively few studies on HCV genotype 6 compared to hepatitis C virus (HCV) genotype 1. In Hong Kong, a city of about 7 million people, most patients infected with HCV are infected with either genotype 1b or 6a. It is known that HCV 6 is of intermediate responsiveness (i.e., between that of HCV genotype 1 and HCV genotypes 2/3) to standard combination interferon/ribavirin therapy. This study examines the molecular epidemiology of chronic HCV 6a infection in Hong Kong during 1999–2005, as well as characterizing some pre- and post-treatment changes in the NS5B gene in a few patients that underwent combination treatment. Partial non-structural protein sequences (NS5B, the viral RNA-dependent RNA polymerase gene, positions 397–1,082) were cloned and sequenced in samples from 51 patients that were obtained and archived during 1999–2005. There were three patients with paired pre- and post-treatment samples available for further analysis. Within this NS5B sequence, one significant amino acid mutation was found in each of these patients: Ser272Pro (end-of-treatment response but relapsed), Met312Thr (failed treatment after 3 months due to anemia), and Arg221Lys (end-of-treatment-response but relapsed). This analysis of the pre- and post-treatment NS5B sequences, suggests that whilst post-treatment mutations were identifiable in individual patients, there was no overall characteristic mutation pattern associated with treatment that was common to all treated patients, identified in this small study. Larger studies are required to confirm these findings. J. Med. Virol. 81:628–633, 2009 © 2009 Wiley-Liss, Inc.